Category: Clinical Trials

The field of glucagon-like peptide (GLP) agonist research continues to show strong momentum, with industry reporting pointing to an expanding pipeline of clinical trials investigating this class of peptide therapeutics. GLP-based compounds have already transformed treatment approaches in metabolic health, and the growing trial activity suggests continued interest from researchers and drug developers in exploring their potential even further.

GLP agonists work by mimicking naturally occurring hormones involved in regulating blood sugar, appetite, and metabolism. Their success in recent years has helped validate peptide-based approaches more broadly, encouraging additional investment and scientific attention toward refining and expanding this therapeutic category. A larger pipeline often signals that developers see meaningful opportunities to build on existing successes, whether through new formulations, combination approaches, or applications beyond the original indications.

An expanding clinical trial landscape is generally a positive signal for patients and the broader medical community. More trials mean more opportunities to gather data on safety, efficacy, and optimal use, which can ultimately lead to refined treatment options and expanded understanding of how these peptides function in the body. It also reflects healthy competition and innovation within the pharmaceutical and biotech sectors, which can help drive improvements in accessibility and treatment design over time.

For the peptide research community, this kind of sustained pipeline growth is encouraging. It suggests that the scientific and commercial interest in GLP agonists remains robust, supporting continued exploration of how these molecules might be optimized or adapted for various metabolic and health-related applications. As more trials progress through various phases, the field will continue to benefit from the accumulated knowledge and experience gained along the way.

True North Labs will continue to monitor developments in the GLP agonist space as new trial data and pipeline updates emerge. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Glucagon-Like Peptide Agonist Clinical Trial Pipeline Gains – openPR.com

A newly registered clinical trial is set to explore an innovative treatment approach for patients facing metastatic melanoma that has spread to the liver, a particularly challenging form of the disease. The study will evaluate whether combining the Hepzato Kit—a liver-directed therapy—with Opdualag, a dual immune checkpoint inhibitor combining nivolumab and relatlimab, can offer better results than current standard approaches.

Liver metastases from melanoma have historically been difficult to treat, often responding less favorably to systemic immunotherapy alone compared to metastases in other locations. By pairing a localized liver treatment with a systemic immune-boosting therapy, researchers hope to create a synergistic effect that could enhance tumor control in this specific area while maintaining the broader anti-cancer benefits of checkpoint inhibition.

The trial’s primary goals include assessing the safety and tolerability of this combination approach, which is an essential first step before determining its potential effectiveness. Researchers will compare outcomes from this combined treatment strategy to a historical cohort of patients who received combination immune checkpoint inhibitor therapy alone, providing a meaningful benchmark for evaluating whether the addition of Hepzato Kit offers measurable advantages.

This research represents an encouraging step forward in the ongoing effort to develop more effective, targeted treatment strategies for patients with advanced melanoma and liver involvement. If successful, this combination approach could potentially offer a new option for a patient population that currently faces limited and often less effective treatment pathways. The study reflects the broader trend in oncology toward combining localized and systemic therapies to address the unique challenges presented by metastatic disease in specific organs.

As with all clinical trials, this research will proceed through careful phases to establish safety before any conclusions about broader effectiveness can be drawn. Patients and families interested in melanoma treatment advances should view this as part of the ongoing scientific process that may eventually lead to improved care options. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

A new clinical trial has been launched to explore how the immunotherapy drug tislelizumab might work even better when paired with other investigational agents in the fight against non-small cell lung cancer (NSCLC). This master protocol study is structured thoughtfully, with two distinct sub-studies designed to capture a broader range of patients — one focusing on those with high PD-L1 expression (50% or more) and another on patients with low or negative PD-L1 expression (less than 50%).

This dual-track approach is encouraging because it reflects a growing understanding in oncology that one-size-fits-all treatments rarely serve every patient equally well. By tailoring sub-studies according to biomarker status, researchers aim to gather more precise data on how different patient populations respond to combination therapy, potentially paving the way for more personalized and effective treatment strategies down the road.

Tislelizumab, a checkpoint inhibitor that helps the immune system recognize and attack cancer cells, has already shown promise in various cancer treatment settings. Testing it alongside new investigational agents — with or without traditional chemotherapy — reflects the kind of innovative thinking that could expand the toolkit available to clinicians treating lung cancer, one of the most common and challenging cancers to manage.

What makes this study particularly hopeful is its focus on antitumor activity, safety, and tolerability together. Rather than chasing efficacy alone, the trial design acknowledges that any new combination must also be manageable for patients in terms of side effects and overall quality of life. This balanced approach is a hallmark of responsible, patient-centered clinical research.

While results from this study are still forthcoming, its initiation marks another meaningful step in the ongoing effort to improve outcomes for people living with NSCLC. Trials like this one help build the foundation of knowledge that could one day lead to new treatment options or improved combination protocols. As always, this article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Researchers have launched a promising new Phase I/II clinical trial designed to explore whether a combination of three monoclonal antibodies—tafasitamab, retifanlimab, and rituximab (together known as TRR)—can enhance the effectiveness of standard chemotherapy regimens for patients with untreated diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma.

The trial, registered on ClinicalTrials.gov, will evaluate this three-antibody combination both as an initial ‘prephase’ treatment and alongside established chemotherapy protocols such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or the newer PolaCHP regimen, which incorporates polatuzumab vedotin. Each of the antibodies works through a distinct and complementary mechanism: tafasitamab targets CD19, rituximab targets CD20, and retifanlimab works as a checkpoint immunotherapy agent designed to help the immune system better recognize and attack cancer cells.

What makes this approach particularly encouraging is the strategy of layering multiple immune-focused therapies on top of proven chemotherapy backbones, rather than replacing them. By combining antibodies that attack cancer cells directly with an immunotherapy designed to unleash the body’s own immune defenses, researchers hope to achieve deeper and more durable responses than chemotherapy alone has historically provided. This kind of combination strategy reflects a broader trend in oncology research toward precision immunotherapy approaches that work with the body’s natural defenses rather than relying solely on traditional cytotoxic treatment.

Diffuse large B-cell lymphoma remains one of the more aggressive blood cancers, and while standard chemotherapy regimens have helped many patients, there has been a strong push within the research community to find ways to improve first-line treatment outcomes. Trials like this one represent an important step in that direction, testing whether newer monoclonal antibody combinations can be safely integrated into established treatment pathways without compromising patient safety.

As this is an early-phase trial, its primary goals include establishing safety and determining appropriate dosing before any conclusions about effectiveness can be drawn. Still, the design reflects thoughtful, incremental scientific progress toward more effective lymphoma treatments, and successful early results could pave the way for larger trials in the future. Patients and families interested in ongoing lymphoma research can find more information through ClinicalTrials.gov.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Researchers have launched a promising new Phase I/II clinical trial designed to explore whether a combination of three monoclonal antibodies—tafasitamab, retifanlimab, and rituximab (together known as TRR)—can enhance the effectiveness of standard chemotherapy regimens for patients with untreated diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma.

The trial, registered on ClinicalTrials.gov, will evaluate this three-antibody combination both as an initial ‘prephase’ treatment and alongside established chemotherapy protocols such as CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or the newer PolaCHP regimen, which incorporates polatuzumab vedotin. Each of the antibodies works through a distinct and complementary mechanism: tafasitamab targets CD19, rituximab targets CD20, and retifanlimab works as a checkpoint immunotherapy agent designed to help the immune system better recognize and attack cancer cells.

What makes this approach particularly encouraging is the strategy of layering multiple immune-focused therapies on top of proven chemotherapy backbones, rather than replacing them. By combining antibodies that attack cancer cells directly with an immunotherapy designed to unleash the body’s own immune defenses, researchers hope to achieve deeper and more durable responses than chemotherapy alone has historically provided. This kind of combination strategy reflects a broader trend in oncology research toward precision immunotherapy approaches that work with the body’s natural defenses rather than relying solely on traditional cytotoxic treatment.

Diffuse large B-cell lymphoma remains one of the more aggressive blood cancers, and while standard chemotherapy regimens have helped many patients, there has been a strong push within the research community to find ways to improve first-line treatment outcomes. Trials like this one represent an important step in that direction, testing whether newer monoclonal antibody combinations can be safely integrated into established treatment pathways without compromising patient safety.

As this is an early-phase trial, its primary goals include establishing safety and determining appropriate dosing before any conclusions about effectiveness can be drawn. Still, the design reflects thoughtful, incremental scientific progress toward more effective lymphoma treatments, and successful early results could pave the way for larger trials in the future. Patients and families interested in ongoing lymphoma research can find more information through ClinicalTrials.gov.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

A newly launched clinical trial, known as the COSMYC Trial, is investigating a promising combination strategy for patients facing castration-resistant prostate cancer — a challenging form of the disease that no longer responds to standard hormone-suppressing treatments. The study aims to determine whether sequencing therapies in a novel order can improve outcomes for patients who have run out of many conventional options.

The trial design is notable for its innovative approach: researchers will first administer a combination of testosterone and the investigational compound ZEN-3694, followed by a second phase combining enzalutamide with ZEN-3694. The hypothesis is that this specific sequencing may prime tumors to respond more effectively to the subsequent enzalutamide-based treatment, potentially enhancing the overall anti-cancer effect compared to standard approaches.

ZEN-3694 belongs to a class of drugs known as BET inhibitors, which work by targeting proteins involved in the regulation of cancer-related genes, including MYC — a gene frequently implicated in aggressive and treatment-resistant cancers. By pairing this mechanism with hormone therapy in a carefully planned sequence, researchers hope to outsmart the biological pathways that allow prostate cancer cells to resist standard treatments.

This kind of research reflects a broader and encouraging trend in oncology: the exploration of smart combination and sequencing strategies rather than relying on a single drug alone. For patients with castration-resistant disease, who often face limited treatment options, trials like COSMYC represent meaningful efforts to expand what’s possible and potentially extend the effectiveness of existing therapies through thoughtful scientific design.

While it will take time before results are available, the launch of this trial is a hopeful sign of continued innovation in prostate cancer research. Patients and clinicians interested in learning more can find additional details through the official clinical trial registry. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: The COSMYC Trial (COmbined Suppression of MYC)

A new clinical trial has opened to study sonrotoclax (BGB-11417) in children and adolescents facing relapsed or refractory acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (ALL). These are forms of blood cancer that can be especially challenging to treat once they return after initial therapy or fail to respond, making new investigational approaches like this one meaningful for families and care teams searching for additional options.

The trial will evaluate sonrotoclax in combination with other established anti-cancer medicines, with researchers closely tracking safety, tolerability, and how the body absorbs, processes, and clears the drug. Participants will undergo regular monitoring, including physical exams, blood tests, and heart health checks, ensuring that safety remains a central focus throughout the study. Researchers will also assess how well the combination therapy helps reduce or eliminate leukemia in these young patients.

What makes this study particularly encouraging is its focus on a patient population that often has limited treatment pathways. By specifically designing a trial for children and adolescents—rather than relying solely on data from adult studies—researchers aim to generate dedicated safety and efficacy information for this age group. Participants will continue treatment for as long as it provides benefit and side effects remain manageable, reflecting a patient-centered approach to care.

Early-phase trials like this one play a critical role in the broader drug development pipeline. They help determine whether a promising compound can be safely combined with existing therapies and whether it shows signals of effectiveness that could support larger studies down the road. For families affected by pediatric leukemia, the launch of this trial represents another step forward in the ongoing effort to expand treatment possibilities for relapsed or hard-to-treat cases.

As with all clinical research, results will take time to emerge, and enrollment and outcomes will be closely monitored by the research team. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia

A new Phase 3 clinical trial has begun enrolling participants to evaluate treatment regimens containing quabodepistat, an investigational compound being studied for its potential to help combat drug-resistant tuberculosis (TB). This randomized, multicenter study represents an important step forward in the ongoing effort to find faster and more effective treatments for one of the world’s most persistent infectious diseases.

The trial is structured around two patient cohorts based on whether their TB strain is susceptible or resistant to fluoroquinolone antibiotics. In the fluoroquinolone-susceptible group, researchers will compare a shortened four-month experimental regimen combining bedaquiline, pretomanid, quabodepistat, and moxifloxacin against the current six-month standard-of-care combination. If successful, this could mean patients spend two fewer months undergoing treatment, a meaningful improvement for quality of life and treatment adherence.

For participants with fluoroquinolone-resistant TB, a six-month quabodepistat-based regimen will be compared to existing therapy. Including this harder-to-treat population is especially valuable, as drug-resistant TB strains have historically posed some of the greatest challenges in infectious disease treatment, often requiring longer and more complex drug combinations.

With approximately 532 participants planned across both cohorts, the study is designed with rigorous safeguards, including a blinded Endpoint Adjudication Committee that will independently confirm treatment outcomes. This level of scientific oversight reflects a strong commitment to generating reliable, trustworthy data that could eventually inform updated treatment guidelines for drug-resistant pulmonary TB worldwide.

Shortening TB treatment duration while maintaining or improving efficacy has long been a goal for researchers and public health officials, as longer treatment courses can strain healthcare systems and make it harder for patients to complete their full regimen. Trials like this one offer hope that new drug combinations may soon make treatment more manageable for patients facing this serious disease.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

Arch Biopartners has announced plans to expand its ongoing Phase 2 clinical trial evaluating its LSALT peptide, extending the study’s reach into the United States. This geographic expansion represents a meaningful milestone for the company’s drug development program, as it opens the door to a larger and more diverse pool of trial participants.

LSALT peptide has been under investigation for its potential therapeutic applications, and the decision to broaden recruitment into the U.S. market signals growing confidence in the trial’s progress and design. Expanding a trial internationally often reflects positive momentum, as companies typically pursue such growth when early data and operational experience support scaling up patient enrollment.

Bringing U.S. clinical sites into the fold can accelerate the pace of enrollment, which is often one of the most time-consuming aspects of clinical research. A broader participant base across multiple countries can also help generate more robust and generalizable data, potentially strengthening the overall evidence package as the peptide moves through the development pipeline.

For patients and the broader peptide research community, news like this underscores the continued interest in peptide-based therapeutics and the steady progress being made in bringing novel treatments through the rigorous phases of clinical testing. Expansions of this nature also reflect growing collaboration between biotech companies and regulatory frameworks that support multi-national trial designs.

As Arch Biopartners moves forward with this expanded trial footprint, the peptide research field continues to demonstrate steady advancement. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Arch Biopartners to Expand Ongoing Phase 2 LSAT Peptide Trial to The US – Yahoo Finance